Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction

Multiple blood markers profiling study

So Young Park, Jinkwon Kim, Ok Joon Kim, Jin Kyeoung Kim, Jihwan Song, DongAh Shin, Seung Hun Oh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

Original languageEnglish
Article numberR45
JournalCritical Care
Volume17
Issue number2
DOIs
Publication statusPublished - 2013 Mar 16

Fingerprint

Fatty Acid-Binding Proteins
Cerebral Infarction
Interleukin-6
Stroke
Neurocalcin
Biomarkers
Odds Ratio
Phosphopyruvate Hydratase
Glial Fibrillary Acidic Protein
Plasminogen Activator Inhibitor 1
Matrix Metalloproteinase 9
Hemostatics
Blood-Brain Barrier
ROC Curve
C-Reactive Protein
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

@article{851d4628a0e14ffb9254f8c85124ecb5,
title = "Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: Multiple blood markers profiling study",
abstract = "Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95{\%} CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95{\%} CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.",
author = "Park, {So Young} and Jinkwon Kim and Kim, {Ok Joon} and Kim, {Jin Kyeoung} and Jihwan Song and DongAh Shin and Oh, {Seung Hun}",
year = "2013",
month = "3",
day = "16",
doi = "10.1186/cc12564",
language = "English",
volume = "17",
journal = "Critical Care",
issn = "1466-609X",
publisher = "BioMed Central Ltd.",
number = "2",

}

Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction : Multiple blood markers profiling study. / Park, So Young; Kim, Jinkwon; Kim, Ok Joon; Kim, Jin Kyeoung; Song, Jihwan; Shin, DongAh; Oh, Seung Hun.

In: Critical Care, Vol. 17, No. 2, R45, 16.03.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction

T2 - Multiple blood markers profiling study

AU - Park, So Young

AU - Kim, Jinkwon

AU - Kim, Ok Joon

AU - Kim, Jin Kyeoung

AU - Song, Jihwan

AU - Shin, DongAh

AU - Oh, Seung Hun

PY - 2013/3/16

Y1 - 2013/3/16

N2 - Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

AB - Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein), inflammatory markers (IL-6, TNF-α, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9), and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination and reclassification for favorable and poor outcome were compared after adding individual or a combination of blood markers to the clinical model of stroke outcome.Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P = 0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome. The addition of a single blood marker to the clinical model did not improve the discriminating ability of the clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus 0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of stroke outcome.

UR - http://www.scopus.com/inward/record.url?scp=84874936878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874936878&partnerID=8YFLogxK

U2 - 10.1186/cc12564

DO - 10.1186/cc12564

M3 - Article

VL - 17

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 2

M1 - R45

ER -